CCRK Inhibitors
Chemical inhibitors of CCRK target the kinase's ATP-binding site, which is essential for its catalytic activity. Purvalanol A, Roscovitine, and Flavopiridol are all potent CDK inhibitors that exhibit their inhibitory effects by competing with ATP for binding to the active site of CCRK. This occupation of the ATP pocket prevents the transfer of a phosphate group to CCRK's substrates, an action that is central to the kinase's function in regulating cell cycle progression. Similarly, Olomoucine and Indirubin-3'-monoxime exert their inhibitory influence on CCRK by binding to this same ATP pocket, rendering the kinase inactive. This blockade directly impedes the phosphorylation events that are critical for the activity of CCRK.
Furthermore, compounds such as Butyrolactone I, R547, SNS-032, and Dinaciclib are characterized by their ability to inhibit CDKs through interference with ATP binding. These chemical inhibitors bind to the ATP-binding site of CCRK, ensuring that the kinase's catalytic activity is halted. The inhibition of CCRK by these chemicals affects its role in cell cycle regulation by preventing the phosphorylation of target proteins. LEE011, Palbociclib, and Abemaciclib follow a similar mode of action by occupying the ATP-binding site of CCRK, which is crucial for its kinase activity. Through this occupation, they effectively inhibit the function of CCRK, blocking its ability to phosphorylate substrates and thus, halting the progression of the cell cycle at points where CCRK activity is necessary. Each of these chemicals acts as a functional inhibitor of CCRK by targeting the kinase's ATP pocket, which is pivotal for its enzymatic activity.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
As a cyclin-dependent kinase (CDK) inhibitor, Purvalanol A directly inhibits CDKs by competing with ATP binding sites. Since CCRK is a member of the CDK family, Purvalanol A can inhibit CCRK's kinase activity, which is crucial for its function in cell cycle regulation. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine is another CDK inhibitor that can directly inhibit CCRK by binding to its ATP pocket, thereby blocking its kinase activity. This inhibition of CCRK can halt its role in cell cycle progression. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol inhibits several CDKs by interfering with ATP binding. Its mechanism can directly inhibit CCRK activity, impeding the phosphorylation of CCRK's substrates involved in the regulation of the cell cycle. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine is a selective CDK inhibitor that can directly inhibit CCRK by competing with ATP for binding to the active site of the kinase, preventing phosphorylation events essential for its activity. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $79.00 $321.00 $671.00 | 1 | |
This compound is a known inhibitor of CDKs, and by the same mechanism, it can inhibit CCRK by blocking ATP binding, which is necessary for its kinase activity. | ||||||
Butyrolactone I | 87414-49-1 | sc-201533 sc-201533A | 200 µg 1 mg | $122.00 $514.00 | 1 | |
Butyrolactone I is a selective inhibitor for CDKs and can inhibit CCRK by interfering with its ATP-binding site, thereby impeding its role in cell cycle regulation. | ||||||
R547 | 741713-40-6 | sc-364596 sc-364596A | 2 mg 5 mg | $375.00 $395.00 | ||
R547 is a potent CDK inhibitor that can inhibit CCRK by blocking its ATP-binding site, preventing the kinase activity that is essential for CCRK's function in cell cycle control. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
SNS-032 is designed to inhibit CDKs and would inhibit CCRK by binding to its ATP pocket, blocking its kinase activity required for cell cycle progression and other functions. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib strongly inhibits various CDKs and would directly inhibit CCRK by binding to its ATP-binding pocket, thereby blocking essential phosphorylation events for its activity. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
LEE011 (ribociclib) is a CDK inhibitor that can inhibit CCRK by interfering with its ATP-binding site, which is crucial for its kinase activity and subsequent cellular functions. | ||||||